Original articleActein (cas 18642-44-9) ameliorates hepatobiliary cancer through stemness and p53 signaling regulation

Add time:09/08/2019    Source:sciencedirect.com

Actein is isolated from the rthizomes of Cimicifuga foetida, which is a triterpene glycoside, displaying suppressive effects on breast cancer cells proliferation. However, the effects of actein treatment on liver injury, tending to cancer, have little to be known. Thus, the study is conducted to explore the role of actein in early liver cancer. Diethylnitrosamine (DEN) was used to induce liver cancer in mice followed by actein treatment at different concentrations. DEN caused steatohepatitis supported by fibrosis and inflammation, which were ameliorated for actein administration. Liver histology of mice with DEN treatment displayed hepatobiliary cysts, reversed by actein. Cell proliferation markers of Cyclin Ds and p53, as well as cancer stem cell markers of CD133 were highly increased in liver tissue samples from DEN-induced mice, and actein showed inhibitory role in these signals expression. Actein-reduced up-regulation of Hif-1α and VEGFR1 in DEN-stimulated liver tissue of mice was seen. Taken together, DEN promoted liver cancer progression, which was ameliorated by actein, supplying a potential therapeutic strategy for liver cancer in future.

We also recommend Trading Suppliers and Manufacturers of Actein (cas 18642-44-9). Pls Click Website Link as below: cas 18642-44-9 suppliers

Prev:A transcriptomic analysis of black cohosh: Actein (cas 18642-44-9) alters cholesterol biosynthesis pathways and synergizes with simvastatin
Next:Original articleActein (cas 18642-44-9) ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant)